Biostate AI India and Narayana Health Partner to Build World’s Largest Cardiac AI Dataset Tailored for Indian Patients
Biostate AI, a global pioneer in AI-driven molecular diagnostics, has announced a groundbreaking partnership between its Indian subsidiary, Bayosthiti AI, and Narayana Health, one of the world’s largest cardiac care networks. Together, the organizations will develop the first artificial intelligence models specifically designed to predict cardiovascular disease in Indian populations, marking a major milestone in precision medicine.
This collaboration seeks to address one of healthcare’s most persistent challenges—the global “data gap”—that leaves millions of South Asian patients underdiagnosed or misdiagnosed because current risk assessment tools are based primarily on Western data.
Closing the “Data Gap” in Cardiovascular Medicine
For decades, nearly all cardiovascular prediction algorithms have been trained on European and North American datasets. As a result, they fail to capture the genetic, molecular, and lifestyle nuances of South Asian populations, who develop heart disease five to ten years earlier than their Western counterparts and often present with different biological markers.
This mismatch has devastating consequences: 65 million Indians suffer from coronary artery disease (CAD), yet diagnostic tools often overlook critical patterns unique to their biology. By leveraging molecular data from 12,000 Indian patients at the Narayana Institute of Cardiac Sciences in Bengaluru, Biostate AI and Narayana Health aim to create a model that reflects the true biological diversity of Indian patients.
The study will analyze complete RNA profiles—the real-time instructions cells use to function—allowing AI to detect early disease signals long before traditional imaging methods reveal structural damage. This represents a transformative shift from reactive to predictive and preventive medicine.
Molecular Innovation at Clinical Scale
This collaboration integrates three rare and powerful components that could redefine how heart disease is detected and prevented:
- Proprietary Molecular Technology:
Biostate AI’s patented BIRT™ (Barcode-Integrated Reverse Transcription) technology enables high-throughput RNA sequencing by processing multiple patient samples simultaneously. This drastically reduces cost and time, making large-scale molecular diagnostics financially viable for national healthcare systems like India’s. - Clinical Scale and Validation:
With over 60,000 cardiac procedures annually, Narayana Health provides both the patient population and real-world clinical environment needed to train and validate AI models against tangible health outcomes. - AI-Powered Precision:
Instead of relying on late-stage imaging or protein markers, Biostate AI’s generative models use RNA sequencing data to identify disease risk 2–3 years before physical symptoms emerge. The system’s accuracy matches invasive diagnostic procedures while offering a non-invasive, scalable solution.
“This partnership represents our strategy in action—bringing breakthrough molecular technology to regions where it can have the greatest impact,” said Dr. David Zhang, CEO of Biostate AI. “By building precision tools for India first, we’re helping define the future of global healthcare.”
From Intervention to Prevention
India faces one of the highest global burdens of heart disease, often striking individuals in their 30s and 40s—decades earlier than in Western countries. Yet most diagnostic algorithms are still calibrated for Western populations, leaving a massive blind spot in preventive care.
“AI-based technologies aren’t the future of medicine—they’re the present,” said Dr. P. M. Uthappa, Group Chief Medical Director at Narayana Health. “This collaboration lets us move from intervention to prevention. The ability to identify high-risk patients earlier and more precisely is a clinical game-changer.”
Early identification allows doctors to intervene with lifestyle changes, medication, or targeted therapies before irreversible damage occurs. Predicting cardiac risk years in advance could prevent countless heart attacks and save millions of lives.
“We’ve relied too long on a one-size-fits-all approach to medicine,” added Kutapa Muthanna, CEO of Bayosthiti AI. “This isn’t just about closing a data gap—it’s about creating proactive, personalized medicine built by Indians, for Indians.”
Teaching AI to Read the Body’s Language
Biostate AI’s models learn disease patterns in the same way that large language models learn human language—through massive datasets. But instead of words, the models process millions of RNA expressions, which represent the “language” of cellular activity.
“Just as AI learns grammar and meaning from billions of sentences, our models learn biological patterns from millions of molecular expressions,” explained Dr. Rishabh M. Shetty, Head of Business Development and Clinical Applications at Bayosthiti AI. “We can detect the molecular conversation that precedes a heart attack—not just the aftermath.”
The three-phase study design will allow continuous refinement of these AI models, paving the way for applications beyond cardiology—potentially extending into diabetes, cancer, and other diseases that disproportionately affect Indian and South Asian populations.
Global Implications, Starting in India
As the dataset grows, the ultimate goal is to develop a blood-based diagnostic test that can be deployed across India’s healthcare system and other South Asian regions. Such a tool could offer cost-effective, early detection on an unprecedented scale.
Bayosthiti AI’s rapidly expanding operations in India have already processed samples from over 100 collaborations worldwide. The Narayana partnership cements its position as a leader in AI-integrated molecular diagnostics.
For Biostate AI, this initiative reflects a broader mission—to merge molecular science, artificial intelligence, and clinical validation to close long-standing healthcare inequities.
“India represents both a challenge and an opportunity,” concluded Dr. Zhang. “If we can solve precision healthcare for 1.4 billion people here, we can solve it for the world.”
Source link :https://www.businesswire.com/
